SCHEMBL20116787

SCHEMBL20116787

CC(C)n1ncc2ccc(-c3nc(C4CCN(C(=O)c5ccc(Cl)cc5)CC4)no3)cc21

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.45
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
MGLL Q99685 1/20 0.41
LMNA P02545 1/20 0.41
TSHR P16473 1/20 0.41
HTT P42858 1/20 0.41
FASN P49327 1/20 0.40
PTGER3 P43115 1/20 0.40
USP7 Q93009 1/20 0.40
GRM5 P41594 1/20 0.39
HTR4 Q13639 2/20 0.38
PROKR1 Q8TCW9 1/20 0.38
USP30 Q70CQ3 1/20 0.38
HSD11B1 P28845 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20116779 0.87 RAB9A (0.44) SMN1; SMN2RAB9AGRM5HSD11B1
SCHEMBL22358562 0.87 HSD11B1 (0.49) SMN1; SMN2RAB9AUSP7HTR4USP30
SCHEMBL22358359 0.85 LMNA (0.54) SMN1; SMN2LMNATSHRHTTGRM5
SCHEMBL20116073 0.85 SMN1; SMN2 (0.41) SMN1; SMN2MGLLHTTPTGER3USP7
SCHEMBL20116225 0.85 SMN1; SMN2 (0.41) SMN1; SMN2HTTUSP7HTR4USP30
SCHEMBL20116077 0.85 SMN1; SMN2 (0.39) SMN1; SMN2LMNATSHRHTTPTGER3
SCHEMBL20116506 0.84 SMO (0.42) SMN1; SMN2NPC1RAB9ALMNAHTT
SCHEMBL20116895 0.83 FASN (0.46) SMN1; SMN2NPC1RAB9ALMNAHTT
SCHEMBL20116783 0.83 SMN1; SMN2 (0.41) SMN1; SMN2MGLLUSP7HTR4USP30
SCHEMBL20117082 0.83 TBK1 (0.44) SMN1; SMN2LMNAHTTPTGER3USP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 US disclosed
WO-2019209948-A9 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-01-02 WO disclosed
WO-2019018795-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2019-01-24 WO disclosed
WO-2018081167-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 SMN1; SMN2 13/4885NPC1 72/4885RAB9A 2129/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 SMN1; SMN2 13/4885NPC1 72/4885RAB9A 2129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.